Who is sponsoring NCT07224490?

NCT07224490 is sponsored by Stephanie B. Seminara, MD.

What condition does NCT07224490 study?

NCT07224490 studies Reproductive Disorder, Neurodegeneration, SARS-CoV 2.

What drugs are being tested in NCT07224490?

Interventions: Kisspeptin 112-121.

What is the status of NCT07224490?

NCT07224490 is currently RECRUITING.

Last reviewed 2026-03-30 · How we verify

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCT07224490 Phase 1 RECRUITING

The objective of this protocol is to use a case-control paradigm to compare the response to an intravenous administration of kisspeptin in individuals with and without post-covid-19 syndrome. The study subjects will receive a single bolus of kisspeptin. This study will utilize the technique of frequent blood sampling (q10 minutes) to provide detailed neuroendocrine characterization of endogenous LH secretion before and after kisspeptin administration. This frequency of blood sampling is required to define the features of LH pulses.

Details

Lead sponsor	Stephanie B. Seminara, MD
Phase	Phase 1
Status	RECRUITING
Enrolment	40
Start date	2026-03-10
Completion	2030-05

Conditions

Reproductive Disorder
Neurodegeneration
SARS-CoV 2

Interventions

Kisspeptin 112-121

Primary outcomes

Difference in mean luteinizing hormone (LH) amplitude between cases and controls — Day of study visit (one to two hours)
Difference between cases and controls of mean LH amplitude in response to kisspeptin

Countries

United States